Molecular Partners AG ADR Market Cap ($164.56 Million)
Market Cap & Net Worth: Molecular Partners AG ADR (MOLN)
Molecular Partners AG ADR market cap. Molecular Partners AG ADR (NASDAQ:MOLN) has a market capitalization of $164.56 Million ($164.56 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17102 globally and #4065 in its home market, demonstrating a 4.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Molecular Partners AG ADR's stock price $4.40 by its total outstanding shares 37399152 (37.40 Million). Also see Molecular Partners AG ADR operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Molecular Partners AG ADR Market Cap History (2021–2026)
Molecular Partners AG ADR market cap history from 2021 to 2026. Data shows change from $717.32 Million to $115.56 Million (-26.53% CAGR). Check Molecular Partners AG ADR (MOLN) share price today for real-time trading data and today's change.
Index Memberships
Molecular Partners AG ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #464 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1671 of 3165 |
Weight: Molecular Partners AG ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Molecular Partners AG ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Molecular Partners AG ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Molecular Partners AG ADR to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
35.73x
Molecular Partners AG ADR's market cap is 35.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $717.32 Million | $9.33 Million | -$63.78 Million | 76.88x | N/A |
| 2022 | $244.96 Million | $189.56 Million | $117.85 Million | 1.29x | 2.08x |
| 2023 | $156.33 Million | $7.04 Million | -$61.98 Million | 22.21x | N/A |
| 2024 | $177.57 Million | $4.97 Million | -$54.04 Million | 35.73x | N/A |
Competitor Companies of MOLN by Market Capitalization
Companies near Molecular Partners AG ADR in the global market cap rankings as of November 4, 2026. Also see Molecular Partners AG ADR total assets for a full breakdown of the balance sheet.
Key companies related to Molecular Partners AG ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Molecular Partners AG ADR (2021–2026)
Market capitalization of Molecular Partners AG ADR from 2021 to today. Between 2021 and today, Molecular Partners AG ADR's market cap moved from $717.32 Million to $ 115.56 Million, with a yearly change of -26.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $115.56 Million | -29.11% |
| 2025 | $163.01 Million | -8.20% |
| 2024 | $177.57 Million | +13.59% |
| 2023 | $156.33 Million | -36.18% |
| 2022 | $244.96 Million | -65.85% |
| 2021 | $717.32 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Molecular Partners AG ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $164.56 Million USD |
| MoneyControl | $164.56 Million USD |
| MarketWatch | $164.56 Million USD |
| marketcap.company | $164.56 Million USD |
| Reuters | $164.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more